Vaccination rates are lagging this year for flu, Covid, and RSV. The CDC has developed key messages and tools for health care providers to use in this final 2023 effort to protect patients before they gather with family and friends for the holidays. Learn about key vaccination messages and access tools from the CDC.


The American Medical Association (AMA) is undertaking a new national study supported by AACE, along with 172 healthcare organizations, to collect representative data on physician practice expenses. Learn how this study will serve as an opportunity to communicate accurate financial information to policymakers, including members of Congress and the Centers for Medicare & Medicaid Services.


This new algorithm provides concise guidance to assist health care professionals with clinical decision-making for the management of persons with type 2 diabetes mellitus and related comorbidities and complications.


In February, 2022, AACE supported an urgent call for action to address the serious health delivery issues that patients with diabetes were facing in the Tigray Region of Ethiopia as a result of the ongoing conflict between the Federal Government and the Tigray Regional Government. We are deeply concerned about the ongoing barriers to delivering life-saving supplies and medications to innocent people of Tigray, suffering with diabetes. Read our full statement to learn more.


Submit your paper for presentation at the first annual Endocrine Practice Journal Symposium at the 2023 AACE Annual Meeting in Seattle, WA.


AACE has been named one of seven subspecialty societies to participate in a Centers for Disease Control and Prevention (CDC)-funded grant project led and coordinated through the Council for Medical Specialty Societies to help increase COVID-19, influenza, and routine vaccinations in high-risk adults with chronic medical conditions.


There is a severe shortage of diabetes medicines in the Tigray region of Ethiopia, jeopardizing thousands of persons with diabetes. We urge both government organizations and non-government organizations, including manufacturers to strive to improve access to life-saving treatments for diabetes in the Tigray region. Read our full statement to learn more.


After over a year of producing virtual events during an uncertain time, we are planning for a potential return to in-person events that brings both excitement and new opportunities. As a valued member of our AACE Community, I would like to be transparent with you and share how we are planning a return to in-person conferences in 2022.


This World Diabetes Day, we at the American Association of Clinical Endocrinology (AACE) extend our support to those in the endocrine care team who help diabetes patients every day. Now with a new brand and name that more clearly defines AACE as a community of individuals who work together to elevate the practice of clinical endocrinology, we are committed to expanding diabetes education with a more inclusive approach — with endocrinologists leading the way. 


Lilly has launched “Insulin Affordability: Learn. Act. Share.” to encourage those who use Lilly insulin to:  

  • Learn about our affordability options 

  • Act by visiting insulinaffordability.com or calling the Lilly Diabetes Solution Center 

  • Share this important information with others who may benefit from our solutions.  


Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.


The U.S. Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg in people with type 2 diabetes.


A new $35 co-pay is available through the Lilly Insulin Value Program in response to the COVID-19 crisis in the U.S.


At this time, the leading pharmaceutical manufacturers are reporting that COVID-19 is NOT having an impact on their manufacturing and distribution capabilities for insulin and other related supplies.


August 18, 2020 (Latest Update)

COVID-19 Resources: Telehealth, Updates and More

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.


As the coronavirus (COVID-19) continues to spread in the United States, it is important for everyone to take the necessary precautions to help prevent infection and spread of the virus. While it is difficult to assess the unique implications of COVID-19 in people with diabetes (type 1, type 2, or gestational) at this time, diabetes and other chronic medical conditions can make patients more vulnerable to infections, leading to serious consequences. In addition, uncontrolled diabetes with hyperglycemia is known to impair immune function.


The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Click to read which models are affected.


The AACE diabetes algorithm is a comprehensive management algorithm that covers lifestyle, obesity, prediabetes, lipids, hypertension and glucose management strategies.


The CDC recently launched in collaboration with Google Health, a prediabetes quiz that will pop up when end users search for certain medical information using their Google browser to bring more public awareness about prediabetes.


Medscape reports the nasal powder, used in the treatment of severe hypoglycemia for patients aged 4 years or older, is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.


Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.


The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.


Findings presented at the AACE 28th Annual Scientific & Clinical Congress showed that seeking hospital care for diabetic ketoacidosis during the weekend as opposed to during the week may increase mortality risk.


Type 2 diabetes (T2D) is associated with increased risk for fractures in the short term but not in the long term, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.


Treatment with linagliptin in patients with type 2 diabetes (T2D) and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events or hospitalization for heart failure, according to results of the CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) presented at the AACE 28th Annual Scientific & Clinic


Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress. 


The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin, according to data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program presented at the AACE 28th Annual Scientific & Clinical Congress.


AACE Member Roy Taylor, MD, discussed the pathogenesis of hepatic insulin resistance in people with type 2 diabetes in an interview at AACE’s 28th Annual Scientific & Clinical Congress.